Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 08, 2016 10:38 AM ET

Healthcare Providers and Services

Company Overview of Genzyme Polyclonals S.A.S.

Company Overview

Genzyme Polyclonals S.A.S. operates as a subsidiary of Genzyme Corporation.

Les Carrés du Parc

10 rue des Rosiéristes - BP 54

Champagne au Mont D´Or

Rhone,  69543



33 4 37 28 16 00


33 4 37 28 16 79

Key Executives for Genzyme Polyclonals S.A.S.

Chief Executive Officer and Chief Operating Officer
Age: 60
Compensation as of Fiscal Year 2015.

Genzyme Polyclonals S.A.S. Key Developments

GENZYME Presents at 7th Annual Life Science CEO Forum, Jan-26-2016 10:30 AM

GENZYME Presents at 7th Annual Life Science CEO Forum, Jan-26-2016 10:30 AM. Venue: Westin Buckhead Hotel, Atlanta GA, United States. Speakers: Stephanie S. Okey, Head of North America, Rare Diseases & Senior Vice President, US General Manager.

Genzyme Announces Positive New Five-Year Investigational Data from the Extension Study of Lemtrada® (alemtuzumab)

Genzyme announced positive new five-year investigational data from the extension study of Lemtrada® (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS). These results will be presented on October 9, 2015 at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. In RRMS patients treated with Lemtrada in the Phase III pivotal studies, the effects described below observed in the two-year trials were maintained through three additional years in the extension study (years three, four and five). After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, 68% of Lemtrada patients from CARE-MS I and 60% from CARE-MS II did not receive additional Lemtrada treatment during the following four years, through month 60. The low annualized relapse rates observed in patients who received Lemtrada in CARE-MS I (0.18) and CARE-MS II (0.27) were maintained from year three (0.19 and 0.22) to year five (0.15 and 0.18). Through year five, 80% and 76% of patients who received Lemtrada in CARE-MS I and CARE-MS II, respectively, did not experience worsening of disability progression confirmed over six months as measured by the Expanded Disability Status Scale (EDSS). Through year five, 33% and 43% of patients who had some disability before receiving Lemtrada in CARE-MS I and CARE-MS II, respectively, had improvement in EDSS score confirmed over at least six months as compared with pre-treatment baseline. Through year five, patients who received Lemtrada in CARE-MS I and II experienced a slowing of brain atrophy as measured by brain parenchymal fraction on magnetic resonance imaging (MRI). In years three, four and five, the median yearly brain volume loss was -0.20% or less, which was lower than what was observed during the two-year pivotal studies. Through year five, the incidence of most adverse events during the extension study was comparable or reduced compared with the pivotal studies. The frequency of thyroid adverse events was high in year three and declined thereafter. The Phase III trials of Lemtrada were randomized, rater-blinded, two-year pivotal studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a (Rebif®) in patients with RRMS who had active disease and were either new to treatment (CARE-MS I) or who had an inadequate response to another therapy (CARE-MS II).

Genzyme Presents at AusBiotech National Conference 2015, Oct-09-2015 11:30 AM

Genzyme Presents at AusBiotech National Conference 2015, Oct-09-2015 11:30 AM. Venue: Victoria, Australia. Speakers: Andre Turenne, Managing Director.

Similar Private Companies By Industry

Company Name Region
Cider Sante SA Europe
Centre Biologique du Chemin Vert Europe
Henry Schein France S.A. Europe
Clinique Ambroise Pare Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Genzyme Polyclonals S.A.S., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at